Investment Rating - The report assigns a rating of "Buy" for the company [4]. Core Insights - The report highlights a rich pipeline for the company in 2026, with expectations for significant clinical data readouts, including results for HER2 ADC, B7H3 ADC, and TROP2 ADC [12][19]. - The target price for the company has been raised to HKD 455.56 based on DCF valuation methods, reflecting increased confidence in the potential global sales peak for several ADC products [8][12]. Financial Summary - Total revenue is projected to grow from RMB 1,462 million in 2023 to RMB 2,516 million by 2027, with a notable increase of 23% in 2026 [3]. - Gross profit margin is expected to improve from 34% in 2025 to 51% in 2027, indicating a positive trend in profitability [3]. - Net profit is forecasted to decrease from RMB -757 million in 2025 to RMB -321 million in 2027, showing a gradual reduction in losses [3]. Pipeline Developments - HER2 ADC DB1303 is undergoing global registration clinical trials for multiple indications, with expected results in 2026 [12][11]. - B7H3 ADC DB1311 is anticipated to initiate a global Phase III clinical trial for 2L CRPC in 2026, following promising data from earlier studies [13][12]. - TROP2 ADC DB1305 is expected to demonstrate comparable efficacy to competitors in the market, with a focus on combination therapies [19][21]. Market Position - The company is positioned to compete effectively in the ADC market, with a strong emphasis on innovative therapies and strategic partnerships [12][19]. - The report notes the potential for the company's ADCs to become next-generation standard treatments in oncology, particularly in combination with other therapies [12][19].

Group 1 - The investment rating for the company is "Recommended" [3] - The core viewpoint of the report emphasizes that the company is positioned as a global source for new drug development, leveraging innovative gene editing technology and a robust antibody platform to drive growth [8][9] - The report highlights three main business segments: preclinical products and services, antibody platform, and clinical research organization (CRO) services, all of which are experiencing high growth due to favorable industry conditions [8][30] Group 2 - The company is expected to achieve significant revenue growth, with projected revenues of 9.80 billion RMB in 2024, 13.52 billion RMB in 2025, and 18.11 billion RMB in 2026, reflecting compound annual growth rates (CAGR) of 41.96% from 2019 to 2024 [2][30] - The net profit is forecasted to increase dramatically, with estimates of 34 million RMB in 2024, 155 million RMB in 2025, and 321 million RMB in 2026, indicating a CAGR of 362.6% from 2024 to 2025 [2][30] - The company has established a strong international presence, with overseas revenue accounting for 68% of total revenue in the first half of 2025, driven by a mature U.S. subsidiary and a diverse customer base [16][43] Group 3 - The report outlines the company's innovative gene editing technology as a key competitive advantage, enabling the development of customized animal models and enhancing the efficiency of drug development processes [48][51] - The antibody development business is expected to grow significantly, with revenues projected to reach 3.18 billion RMB by 2024, supported by a large library of antibody sequences and a flexible revenue model [39][40] - The company has a well-defined growth strategy, focusing on expanding its international market share and enhancing its service offerings to meet the evolving needs of pharmaceutical companies [8][30]

Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 15.97 and a fair value of HKD 19.99 [4]. Core Insights - The company is the world's largest sports shoe manufacturer, driven by both manufacturing and retail operations, with a potential performance turnaround expected [1][9]. - The manufacturing business is expected to see revenue and profitability improvements due to various factors, including a recovery in order placements from brand clients and a favorable market environment in 2026 [9]. - The retail business is actively pursuing multi-channel and refined operations, which are anticipated to lead to a performance rebound [9]. Summary by Sections Company Overview - The company is the largest sports shoe manufacturer globally, with a market share based on annual production [14]. - It has a significant workforce of 285,500 employees, with 265,500 in manufacturing and 20,700 in retail [14]. - The company achieved a revenue of USD 8.182 billion in FY2024, reflecting a year-on-year growth of 3.7% [2][14]. Manufacturing Business - The manufacturing segment contributed 68.7% of total revenue and 85.2% of profit in FY2024, with revenues of USD 5.621 billion, up 11.1% year-on-year [17]. - The average selling price (ASP) for shoes was USD 20.25, down 5.1% year-on-year due to a higher concentration of high-end products in previous years [17]. - The company has a diversified production base across several countries, with significant output from Indonesia, Vietnam, and China [15][17]. Retail Business - The retail segment, operated through the subsidiary BaoSheng International, generated USD 2.561 billion in FY2024, a decrease of 9.5% year-on-year [24]. - The company is optimizing its store network, reducing the number of direct-operated stores to 3,448 while improving average store size [24]. - The retail business is expected to benefit from improved discount rates and effective inventory management [9]. Financial Projections - The company forecasts earnings per share (EPS) of USD 0.23, USD 0.26, and USD 0.28 for FY2025, FY2026, and FY2027, respectively [9]. - The report estimates a fair value of HKD 19.99 per share based on a sum-of-the-parts valuation method [9]. Market Performance - The company's stock price has shown significant volatility, with a historical increase of 2044.24% since its listing in 1992, although it has faced challenges in recent years due to external market conditions [46]. - The company’s price-to-earnings (P/E) ratio has fluctuated between 7 and 18 times, indicating a relatively low valuation compared to historical levels [46].

港股公司 证 券 研 究 报 告 康耐特光学（02276.HK）重大事项点评 强推（维持） 智能眼镜首次纳入国补，看好消费级产品渗 透率加速提升 事项： ❖ 25 年 12 月 30 日，国家发改委、财政部发布 2026 年国补政策，首次将智能眼 镜纳入补贴范围，补贴标准为 15%，单件补贴上限 500 元（单件产品售价不超 过 6000 元）。根据测算，智能眼镜价格超过 3300 元基本可以全额享受国补。 评论： 其他轻工Ⅲ 2025 年 12 月 31 日 | 目标价：63.63 | 港元 | | --- | --- | | 当前价：51.80 | 港元 | 华创证券研究所 证券分析师：刘一怡 邮箱：liuyiyi@hcyjs.com 执业编号：S0360524070003 联系人：周星宇 邮箱：zhouxingyu1@hcyjs.com ❖ 风险提示：智能眼镜发展不及预期、国内渠道拓展不及预期、行业竞争加剧。 [主要财务指标 Indicator_FinchinaSimpleHK] | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | ...

Investment Rating - The report initiates coverage with an OUTPERFORM rating for Softcare, indicating a positive outlook compared to the market [1][2]. Core Insights - Softcare is positioned as a leading player in the hygiene products sector within emerging markets, focusing on localized deployment to build a competitive moat [1][4]. - The company has a strong market presence in Africa, with leading market shares in baby diapers (20.3%) and sanitary napkins (15.6%) based on 2024 sales volume [4][9]. - The growth drivers include demographic advantages and low penetration rates in the hygiene products market, which present significant growth potential [4][29]. Financial Performance - Revenue projections for Softcare show a steady increase, with expected revenues of $551 million in 2025, representing a 21% year-over-year growth [7]. - Net profit is projected to reach $112 million in 2025, reflecting a 14% increase from the previous year [7]. - The company maintains a gross profit margin (GPM) of approximately 34.2% for 2025, indicating stable profitability [7][24]. Market Dynamics - The African market for baby and female hygiene products is characterized by a young population and increasing urbanization, which are expected to drive demand [28][29]. - The penetration rates for baby diapers and sanitary napkins in Africa are significantly lower than in developed markets, suggesting ample room for growth [29][31]. - The report highlights that the African hygiene products market is projected to grow at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2029, outpacing other regions [33]. Competitive Advantages - Softcare has developed a diversified brand strategy with over 340 SKUs across four core categories, enhancing its market reach [5]. - The company has established a localized production model with eight factories across eight African countries, which reduces costs and improves supply chain efficiency [5][6]. - A multi-channel sales network has been developed, reaching over 80% of the local population in key markets [5]. Future Growth Strategy - Softcare plans to replicate its successful African model in Latin America and other emerging markets, aiming to create a sustainable second growth curve [6]. - The company is focused on expanding its product categories through both organic growth and strategic acquisitions [6]. Valuation - The report assigns a target price of HK$40.50, based on a price-to-earnings (P/E) ratio of 25x for 2026, reflecting the company's strong market position and growth potential [7].

公司研究 心律管理业务重组合并，母公司亏损如期收窄中 2025 年 12 月 31 日 ——微创医疗（0853.HK）跟踪点评 要点 事件：公司近期公告 1）根据微创医疗集团会计政策其无法控制微创脑科学但仍 对其保持重大影响力，故终止合并微创脑科学，构成须予披露交易。2）微创心 通召开股东大会，审议通过并购微创心律管理有限公司的重大资产重组议案。此 次并购将推动微创医疗旗下结构性心脏病与心律管理两大核心业务板块的深度 整合。 点评： 治理结构改善注入新动能，出海业务成为核心增长引擎。公司治理层面，上实资 本旗下基金成为公司重要战略股东，有望在治理和业务发展方面注入新动能。公 司近期完成心律管理与结构性心脏病业务的重组，旨在打造综合心脏病平台，新 公司将融合微创心律管理的 AI 诊断及算法技术，与微创心通在结构性心脏病介 入治疗、输送系统及生物材料方面的技术积累，打造"结构性心脏病+心律管理 +心衰管理"一体化平台。公司亦公告终止合并微创脑科学，我们认为治理改善 持续推进中。同时，公司积极搭建全球通商业化平台，助力各业务板块产品出海， 25H1 出海业务收入已达 5,980 万美元，同比增长 57.3%，有效对 ...

Investment Rating - The report assigns a "Buy" rating for VTech Holdings, marking its first coverage [3][8]. Core Insights - VTech Holdings is a leading global player in electronic learning products for infants and preschoolers, as well as a major manufacturer of home telephones. The company has a strong brand presence and a diversified product portfolio, including electronic learning toys, telecommunications products, and contract manufacturing services [7][20]. - The company is expected to achieve revenues of $2.177 billion in 2025, with a slight growth of 1.5% year-on-year. However, net profit is projected to decline by 5.9% to $157 million in the same year [2][8]. - The electronic learning products segment is anticipated to generate $830 million in revenue for the fiscal year 2025, with a compound annual growth rate (CAGR) of 2% from 2015 to 2025. The company holds a 12% market share in the U.S. infant and preschool toy market [7][64]. Financial Data and Profit Forecast - Revenue and profit forecasts for VTech Holdings from 2024 to 2028 are as follows: - Revenue: $2,146 million (2024), $2,177 million (2025), $2,006 million (2026), $2,046 million (2027), $2,099 million (2028) - Net Profit: $167 million (2024), $157 million (2025), $149 million (2026), $160 million (2027), $171 million (2028) - Earnings per Share: $0.66 (2024), $0.62 (2025), $0.59 (2026), $0.63 (2027), $0.68 (2028) [2][8]. Business Segments - **Electronic Learning Products**: This segment is a key growth driver, with a strong brand and high customer loyalty. The U.S. market for educational toys is projected to grow significantly, driven by parents' demand for quality educational products [7][64][56]. - **Telecommunications Products**: Despite a declining global fixed-line market, VTech's telecommunications segment is expected to grow by 37% in 2025, primarily due to the acquisition of Gigaset, which enhances its product offerings and market reach [7][11][19]. - **Contract Manufacturing Services**: This segment has shown steady growth, with revenues expected to rise from $530 million in 2015 to $930 million in 2025, reflecting a CAGR of approximately 6% [7][19]. Market Position and Competitive Advantage - VTech has established a strong market position in the electronic learning products sector, with significant barriers to entry for competitors. The company has successfully integrated acquisitions to enhance its product offerings and expand its market presence [7][11][60]. - The telecommunications segment benefits from a stable demand for home security and communication systems, positioning VTech favorably against market perceptions of being in a declining industry [11][19]. Dividend Policy - VTech has maintained a high dividend payout ratio, consistently returning over 90% of its net profits to shareholders since 2009, indicating strong shareholder returns [8][19].

Investment Rating - The report gives a "Buy" rating for the company with a target price of HKD 18.1, representing a potential upside of 64% from the current price of HKD 10.98 [1]. Core Insights - The report emphasizes that the "takeaway war" has ignited a new journey in instant retail, termed "everything to home," highlighting the significant growth potential in the instant retail sector [4][21]. - The company is identified as the largest third-party instant delivery service platform in China, benefiting from the synergy of its independent third-party status and the broader ecosystem of SF Express [8][9]. - Financial performance shows a continuous improvement in profitability, with gross margins increasing from -23.3% in 2018 to 6.8% in 2024, and adjusted net profit margins improving from -36.4% to 0.93% over the same period [8][9]. Summary by Sections Instant Retail Market - Instant retail is characterized by online ordering and offline fulfillment, aiming to meet local immediate demands, with a projected market size of RMB 781 billion in 2024, growing at 20.15% year-on-year [4][38]. - The competition among major players like Meituan, Taobao, and JD has intensified, with significant subsidies driving daily order volumes to record highs [13][14][15]. - The report outlines three main service models in instant retail: front warehouses, comprehensive instant retail platforms, and store-warehouse integrated self-operated models [23][26][30]. Company Overview - The company is positioned as the leading third-party instant delivery service provider, leveraging the SF Express brand reputation and service capabilities to create a synergistic effect [8][9]. - The internal and external growth mechanisms, termed "dual flywheel," are driving significant revenue growth, with a forecasted increase in net profit from RMB 132 million in 2024 to RMB 707 million by 2027 [9][5]. Financial Projections - Revenue is expected to grow from RMB 15.746 billion in 2024 to RMB 32.731 billion by 2027, with a compound annual growth rate (CAGR) of 27.1% [5]. - The adjusted net profit is projected to reach RMB 8.1 billion by 2027, with a corresponding adjusted price-to-earnings (PE) ratio decreasing from 25 in 2025 to 11 in 2027 [9][5].

Investment Rating - The report maintains a "Buy" rating for 威胜控股 (3393.HK) and raises the target price to HKD 19.58 [1][4][6]. Core Insights - 威胜控股's ADO business is entering a rapid growth phase driven by strong demand in the data center sector, with significant orders already secured from major clients such as 万国数据 and 字节 [2][3]. - The partnership with 博裕投资 is expected to enhance 威胜控股's business development through capital and industrial resource collaboration, leveraging 博裕's extensive experience in data centers, technology, and renewable energy [1][3]. - The company's financial forecasts indicate a net profit growth rate exceeding 30% for both 2025 and 2026, supported by the booming data center business [4][5]. Financial Summary - Sales revenue is projected to grow from RMB 7.25 billion in FY 2023 to RMB 10.61 billion in FY 2025, reflecting a growth rate of 21.7% [5][12]. - Net profit is expected to increase from RMB 521.23 million in FY 2023 to RMB 923.22 million in FY 2025, with a growth rate of 30.8% [5][12]. - The gross margin is forecasted to remain stable around 34.6% from FY 2025 onwards, while the net profit margin is expected to improve to 8.7% by FY 2025 [5][12]. - The company is also projected to achieve a return on equity (ROE) of 11.9% in FY 2025, increasing to 15.2% by FY 2027 [5][12]. Market Position - 威胜控股's ADO business is strategically positioned to capitalize on the explosive growth in data center demand, both domestically and internationally, particularly benefiting from the rise of AI technologies [2][3]. - The company holds approximately 65% of the shares in its subsidiary, 惟远能源, which operates the ADO business [2][3].

证券研究报告：食品饮料 | 公司点评报告 股票投资评级 买入|维持 个股表现 -50% 0% 50% 100% 150% 200% 250% 2024-12-27 2025/3/13 2025/5/29 2025/8/8 2025/10/21 优然牧业 食品饮料 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价(港元） | 4.94 | | | --- | --- | --- | | 总股本/流通股本(亿股) | 38.93 | | | 总市值/流通市值(亿港 | 192 | | | 元） | | | | 52 周高/低(港元） | 5.12 /1.47 | | | 资产负债率(%) | 71.77 | | | 市盈率 PE | 58.2 | | | 第一大股东 | PAGAC | Yogurt | | | Holding II Limited | | 研究所 分析师:蔡雪昱 SAC 登记编号:S1340522070001 Email:caixueyu@cnpsec.com 分析师:张子健 SAC 登记编号:S1340524050001 Email:zhangzijian@cnpsec.com 优 ...